Assenagon Asset Management S.A. Vaxcyte, Inc. Transaction History
Assenagon Asset Management S.A.
- $60.5 Billion
- Q2 2025
A detailed history of Assenagon Asset Management S.A. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Assenagon Asset Management S.A. holds 47,976 shares of PCVX stock, worth $1.74 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
47,976
Previous 323,565
85.17%
Holding current value
$1.74 Million
Previous $12.2 Million
87.24%
% of portfolio
0.0%
Previous 0.02%
Shares
3 transactions
Others Institutions Holding PCVX
# of Institutions
341Shares Held
136MCall Options Held
348KPut Options Held
250K-
Ra Capital Management, L.P. Boston, MA12.2MShares$442 Million9.56% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$436 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X011.8MShares$426 Million0.25% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$360 Million0.02% of portfolio
-
Wellington Management Group LLP Boston, MA6.42MShares$233 Million0.05% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $2.15B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...